Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

  • Exchange: NASDAQ CM
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Specialty Pharma

TG Therapeutics Inc

+ Add to Watchlist

TGTX:US

16.4900 USD 0.6800 3.96%

As of 20:10:00 ET on 04/17/2015.

Snapshot for TG Therapeutics Inc (TGTX)

Open: 16.9700 Day's Range: 16.1500 - 17.2300 Volume: 631,499
Previous Close: 17.1700 52wk Range: 4.4200 - 20.0000 1-Yr Rtn: +212.90%

Stock Chart for TGTX

No chart data available.
  • TGTX:US 16.4900
  • 1D
  • 1M
  • 1Y
17.1700
Interactive TGTX Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for TGTX

Current P/E Ratio (ttm) -
Estimated P/E(12/2015) -
Relative P/E vs. SPX -
Earnings Per Share (USD) (ttm) -1.6000
Est. EPS (USD) (12/2015) -1.4280
Est. PEG Ratio -
Market Cap (M USD) 767.51
Shares Outstanding (M) 46.54
30 Day Average Volume 701,113
Price/Book (mrq) 9.2500
Price/Sale (ttm) 3,652.9283
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 05/12/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for TGTX

  • Revenue
  • Net Income (M/USD)
  • Profit Margin (%)

Company Profile & Key Executives for TGTX

TG Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of innovative pharmaceutical products for the treatment of cancer and other underserved therapeutic needs. Currently, the company is developing two therapies targeting hematological malignancies, specifically, relapsed and refractory non-Hodgkins lymphoma.

Michael S Weiss "Mike"Chairman/Interim Pres & CEOSean A PowerCFO/Treasurer/Secretary
Jenna BoscoDirector:Investor Relations
More Company Profile & Key Executives for TGTX

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil